ClinicalTrials.gg
RecruitingNCT06834633NephroTraumaUpdated Jul 29, 2026

Nephroprotection in Severe Trauma Patients With Kidney Stress

An interventional study of Standard-of-care and Systematic nephroprotection bundle-of-care in Trauma; Complications, sponsored by Hospices Civils de Lyon. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
523
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Acute Kidney Injury (AKI) occurs in 24% of trauma patients, and is even more common in those with severe trauma. It is a major contributor to morbidity and mortality in trauma. Diagnosis of AKI is based on elevated serum creatinine and decreased urine output, two functional markers already indicating the presence of a significant kidney function impairment. Earlier detection of kidney stress, at a preclinical stage when cellular modifications are still reversible, could reduce the occurrence of AKI episodes if nephroprotective measures are rapidly implemented.

Several randomized controlled trials have shown that early implementation of such a nephroprotection bundle-of-care in patients at risk of AKI after major surgery reduces the incidence of severe AKI within 72 hours. Although its use is supported by international guidelines, this nephroprotection bundle-of-care is rarely implemented in its totality, due to the significant financial and human resources required for its full implementation.

The Nephrocheck® (NC) test is a urine test for which a result > 0.3 is predictive of AKI development. It might enable early identification of trauma patients at risk of AKI, so that implementation of the nephroprotection bundle-of-care could be targeted solely at those high-risk patients.

Thus, the investigators hypothesize that in a population of severe trauma patients (ISS score>15) at risk of AKI (defined by a NC on Intensive Care Unit (ICU) admission > 0.3), early implementation of a nephroprotection bundle-of-care would reduce the risk of AKI occurring within 3 days of ICU admission, compared with standard-of-care management. This study will compare the occurrence of AKI in these two groups in a multicenter randomized controlled trial.

02

Conditions studied

  • Trauma; Complications

Keywords

  • Severe trauma
  • Acute Kidney Injury
  • Nephroprotection bundle-of-care
  • Biomarker
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's planned enrollment of 523 is above the median of 70 across 1,426 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (≥ 18 years)
  • Severe trauma patients (ISS score > 15) admitted to a trauma center
  • Time between trauma and admission to trauma center \<6h
  • High risk of AKI: at least one NC score greater than 0.3 within 12 hours of admission to critical care (intensive care and continuous monitoring unit)
  • Affiliated with a social security scheme or beneficiary of a similar scheme
  • Consent signed by patient or close relative, or attestation signed by investigator in case of emergency

Exclusion criteria

Exclusion Criteria:

  • Adult under legal protection (guardianship, curators)
  • Persons deprived of their liberty by judicial or administrative decision
  • Patients taking part in other interventional research which may interfere with the research and which includes an exclusion period still in progress at the time of inclusion.
  • Pregnant or breast-feeding woman (diagnosis of pregnancy by plasma βHCG (Beta-Human Chorionic Gonadotropin) assay routinely performed as part of the blood test on admission to the outpatient department of a woman of childbearing age).
  • Patients with end-stage or severe chronic renal failure with (GFR) \< 30 milliliters/min/1.73m2 or chronic dialysis.
  • Anuric patients
  • Severe heart failure defined as (LVEF) \<25%.
  • Patient moribund on admission with an estimated length of stay of less than 24 hours
  • Patient with AKI at time of randomization (developed prior to ICU admission or within the first 12 hours of ICU admission, before randomization).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
523 participants (estimated)

Study arms

  • Other
    Observational group

    Patients in the observational group will be managed according to the unit's standard-of-care, as in the control group, but without investigators knowing the patient's risk of AKI (NC score not known)

    Other: Standard-of-care

  • Other
    Control group: Standard-of-care

    Patients at risk of AKI (NC\>0.3) randomized in the control group will be managed according to the unit's standard-of-care.

    Other: Standard-of-care

  • Experimental
    Intervention group: nephroprotection bundle-of-care

    Patients at risk of AKI (NC\>0.3) randomized in the intervention group will receive the systematic and complete application of a nephroprotection bundle-of-care for three days following ICU admission.

    Other: Systematic nephroprotection bundle-of-care

Interventions

  • OtherStandard-of-care

    Management according to current ICU practices

  • OtherSystematic nephroprotection bundle-of-care

    The nephroprotection bundle-of-care includes 5 components: 1. Prevention of drugs' nephrotoxicity 2. Hemodynamic optimization, for 24h 3. Blood glucose control and avoidance of hyperglycemia 4. Early detection of rhabdomyolysis 5. Monitoring of renal function

06

What researchers measure

Primary outcomes

  1. Proportion of patients developing an AKI episode within 3 days after ICU admission.

    AKI will be defined according to KDIGO (Kidney Disease: Improving Global Outcomes) criteria, either by a drop in urine output (oliguria \< 0.5ml/kg/h for 6h) and/or a rise in serum creatinine (1.5x baseline or increase of 26.5 µmol/l).

    Time frame: During 3 days from ICU admission.

Secondary outcomes

  1. Proportion of patients with AKI within 7 days of ICU admission

    AKI will be defined according to KDIGO criteria, either by a drop in urine output (oliguria \< 0.5ml/kg/h for 6h) and/or a rise in serum creatinine (1.5x baseline or increase of 26.5 µmol/l).

    Time frame: During 7 days from ICU admission

  2. Proportion of patients with severe AKI within 3 days of ICU admission

    Severe AKI is defined as AKI stage 2 or 3 according to KDIGO criteria

    Time frame: During 3 days from ICU admission

  3. Proportion of patients with severe AKI within 7 days of ICU admission

    Severe AKI is defined as AKI stage 2 or 3 according to KDIGO criteria

    Time frame: During 7 days from ICU admission

  4. Proportion of patients with MAKE (MAjor Adverse Kidney Event) 28

    MAKE 28 is defined by the occurrence of one event among (1) death before day 28 after ICU admission, (2) requirement of renal replacement therapy on day 28 or (3) incomplete renal recovery on day 28.

    Time frame: At 28 days after ICU admission

  5. Proportion of patients with a complication among cardiovascular and hemodynamic complications; septic complications; hemorrhagic complications within 7 days after ICU admission

    Cardiovascular or hemodynamic complications include ventricular cardiac rhythm disorders, cardiogenic acute pulmonary edema and poorly controlled arterial hypertension \[MAP (Mean Arterial Pressure) \> 120 mmHg for 4 hours\]. Septic complications correspond to sepsis defined by the association of an infection and an increase in SOFA \>=2. Hemorrhagic complications are defined by the number of packed red blood cells (RBCs) used.

    Time frame: During 7 days after ICU admission.

  6. Proportion of patients with at least one episode of dysglycemia within 3 days after ICU admission

    Episodes of dysglycemia are defined as hypoglycemia (\<4mmol/l) or hyperglycemia (\>12mmol/l).

    Time frame: During 3 days after ICU admission.

  7. ICU and hospital length-of-stay

    Total number of days spent in critical care (intensive care, continuous care) and in the initial hospital

    Time frame: During 28 days from ICU admission

  8. Identification of risk factors for AKI in trauma patients using clinical and laboratory parameters

    Known and novel risk factors for AKI in trauma patients will be evaluated using clinical variables (e.g., age, comorbidities, injury severity scores), hemodynamic parameters (e.g., MAP, lactate), and biomarkers of kidney function (e.g., CPK, TIMP-2/IGFBP-7)

    Time frame: During 7 days from ICU admission

  9. Incidence of AKI in trauma patients within 3 days of ICU admission based on KDIGO Criteria

    The incidence of all stages and severe AKI in trauma patients at risk will be assessed based on the KDIGO criteria

    Time frame: During 3 days after ICU admission

  10. Characterization of AKI episodes phenotype in trauma patients using KDIGO criteria

    Acute Kidney Injury episodes will be characterized based on a combination of factors including : * Time to AKI onset: defined as the time (in hours) from ICU admission to the diagnosis of AKI * Diagnostic criteria: whether the AKI is diagnosed based on serum creatinine or urine output changes * Severity: the highest KDIGO stage (1, 2, or 3) reached during the episode * Duration: transient (\<48h) or persistent (≥48h) AKI.

    Time frame: During 7 days from ICU admission

  11. Proportion of patients receiving the nephroprotection bundle-of-care in its entirety, by component, and by practice.

    The entirety of the nephroprotection bundle-of-care is defined by the combination of at least one practice from each component: medication, hemodynamics, rhabdomyolysis, monitoring, glycemia

    Time frame: During 3 days after ICU admission

  12. Cost-effectiveness incremental ratio of the nephroprotection bundle-of-care compared with standard-of-care at 7 days after ICU admission.

    The incremental cost-effectiveness ratio will be expressed as the additional cost per AKI avoided.

    Time frame: At 7 days after ICU admission

  13. Cost-effectiveness incremental ratio of the nephroprotection bundle-of-care compared with standard-of-care at 28 days after ICU admission.

    The incremental cost-effectiveness ratio will be expressed as the additional cost per AKI avoided.

    Time frame: At 28 days after ICU admission

  14. Average costs of initial hospital stay for each group

    Time frame: During 28 days after ICU admission

07

Study locations

6 of 6 sites recruiting
  • Centre Hospitalier universitaire Estaing, Service anesthésie-réanimation
    Clermont-Ferrand, 63100, France
    Recruiting
  • Centre hospitaler Annecy Genevois, Service de réanimation
    Épagny, 74370, France
    Recruiting
  • Centre hospitalier universitaire de Grenoble Alpes, Pôle anesthésie-réanimation
    La Tronche, 38700, France
    Recruiting
  • Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'anesthésie-réanimation
    Lyon, 69003, France
    Recruiting
  • Hospices Civils de Lyon, Hôpital Lyon-Sud, Service d'anesthésie-réanimation
    Pierre-Bénite, 69310, France
    Recruiting
  • Centre hospitalier universitaire de Saint Etienne, Hôpital Bellevue, Service anesthésie-réanimation
    Saint-Etienne, 42000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2027, 26 months after the start.

Of 546 non-industry interventional studies with no phase under Wounds and Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's planned 26 months is close to that.

Counting every sponsor, half of 599 studies reached it within 24 months; a quarter within 9 and three quarters within 48.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Feb 19, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06834633
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Jul 9, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Céline MONARD
Contact
celine.monard@chu-lyon.fr
04 72 11 13 27 ext. +33
Karine POYAU
Contact
karine.poyau@chu-lyon.fr
04 72 11 53 81 ext. +33
Céline MONARD
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion